Please assess the completion status of the following clinical trial:

Trial Title: Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female~* At least one prescription for bazedoxifene, raloxifene, or any bisphosphonate during the study inclusion period (index prescription);~* A recoded diagnosis code of osteoporosis on or within 60 days prior to the index prescription date;~* Age \>=45 at the date of the index prescription; and~* At least 6-months of follow-up data in the electronic medical record system prior to the date of the index prescription~Exclusion Criteria:~* There is no exclusion criteria. All women in the database who meet the inclusion criteria will be studied.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bazedoxifene (Type: None): None
- Primary Comparator (Type: None): None
- Secondary Comparator (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).